Novocure (NVCR) Misses Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Novocure Reports Second Quarter 2016 Financial Results and Provides Company Update
July 28, 2016 6:30 AM EDTContinued growth in active patients with 891 active patients at June 30, 2016, an increase of 110 percent from second quarter 2015, and 12 percent from first quarter 2016
Second quarter 2016 reported revenues of $17.9 million, reflecting 174 percent growth versus second quarter 2015 and 37 percent growth versus first quarter 2016
Approximately 116 million covered lives in the United States as of June 30, 2016, including an additional 10 million lives placed under coverage during second quarter 2016
National Comprehensive Cancer Network® (NCCN®) published updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers to include Optune as category 2A treatment option for newly diagnosed... More
